With the introduction of self-expanding metal esophageal stents (SEMS), interest in using stents as a palliative option for malignant dysphagia was revived and currently SEMS have virtually replaced the older semi-rigid plastic stents which were associated with high complication rates.[1-5] Some of the advantages of SEMS over semi-rigid plastic stents are thinner delivery system as the stent is constrained to a small diameter; hence pre-insertion dilatation is not required in most patients. Despite the thinner delivery system, the expanded stent can reach diameters larger than the semi-rigid plastic tubes and the expansion is gradual unlike the abrupt stretching from plastic stents. SEMS can conform to the shape of the stricture and hence are ideal for tortuous strictures. It is easy to place SEMS within SEMS if needed. SEMS are covered with a plastic membrane to prevent tissue in-growth but also have partially uncovered segments at the proximal and distal ends for better anchoring with tissue in-growth. Once embedded, they are difficult to remove. Hence SEMS are not FDA cleared for benign indications. However, in the recent past, a self-expanding plastic esophageal stent (SEPS) was introduced (Polyflex stent®). This stent is made of woven plastic strands (potentially induces less tissue reaction compared to metal) and the stent is fully covered. Due to these features, this stent can be removed and is also approved for benign indications. Fully covered metal stents (potentially removable) are also now available and are awaiting FDA clearance for benign indications.

**Keywords:** Esophageal cancer - Malignant dysphagia - Refractory benign esophageal stricture - Esophageal perforation leaks - Fistulae - Self-expanding metal stent - Self-expanding polyflex stent - Biodegradeable esophageal stent
Since the efficacy and safety of expandable stents in palliating advanced malignant dysphagia and fistulae have been well studied and extensively published, this review will focus only on the relatively recent concepts and indications of using SEMS and SEPS in the management of esophageal disorders.

Bridge to Surgery

Traditionally, SEMS and SEPS are used for palliating advanced inoperable esophageal cancers with the intentions of improving quality of life by maintaining an open and functional oro-gastric pathway until the patient’s demise. Their role in patients with resectable disease or those needing neoadjuvant therapy before surgery is not well established. Around 40%-50% of patients fall in this category and almost all present with dysphagia requiring symptom relief. These patients may have to wait for several weeks before surgery, either receiving neoadjuvant therapy or on the wait-list for surgery. There has been some apprehension on placing SEMS in these patients for fear of complications, especially if they are receiving neoadjuvant treatment. This apprehension is based on some studies showing a higher complication rate with SEMS in those who have received prior chemo-radiation.[6,7] Hence, unfortunately these operable patients on neoadjuvant treatment receive a naso-gastric or a PEG tube as a bridge to surgery. Neither of these approaches relieves dysphagia. Naso-gastric tube can be uncomfortable and PEG tubes are not without risks besides the fact that they may interfere with subsequent gastric pull-up surgery. Hence using stents to relieve dysphagia as a bridge to surgery appears to be an attractive option.

Studies to evaluate the efficacy of stents during neoadjuvant therapy for locally advanced esophageal cancer prior to surgery are limited.[8-10] In a recent prospective study,[8] 13 patients with dysphagia who were found to have locally advanced, non-metastatic esophageal cancer on endoscopic ultrasound had a SEPS (Polyflex stent) placed at the time the ultrasound was performed. These patients were considered candidates for neoadjuvant therapy prior to surgery. All patients had significant improvement in dysphagia scores (3 at baseline compared to 1.1, 0.8, 0.9, and 1.0 at 1, 2, 3, and 4 weeks after stenting respectively). Except for one patient with severe chest pain, there were no immediate complications. However, the stent migrated in 6 of 13 patients (46%). Only 3 of 13 patients eventually underwent esophagectomy.

Although the above approach appears attractive compared to naso-gastric or PEG tube placement, it is important to understand that stents do not prolong survival and hence the only rationale to use this approach will be to immediately relieve dysphagia and allow for natural eating while the patient is waiting for definitive therapy. However, experience from stenting advanced cancers for palliation has shown that a significant proportion of these patients may develop stent-related complications.[11] If these also occur in operable patients, it may delay or interfere with chemo-radiation or surgery. Stent related perforation could be disastrous as this may spill malignant cells into the mediastinum or the peritoneal cavity. Although there are studies showing higher complication rates with stents in those who have received prior chemo-radiation,[6,7] there are very few studies looking at the complication rates of stents in those who receive chemo-radiation after stent placement. In one study,[12] of the 3 patients who received SEMS before radiotherapy, one died of perforation 2 months after radiotherapy. In another study on patients receiving radiotherapy 1 week after stenting, elective removal of the stent at 4 weeks was associated with less complications compared to those in whom the stents were not removed.[13] There are no randomized studies looking at the influence of stents on subsequent surgery e.g., difficulties during surgery, anastomotic leaks etc. Similarly no data is available on which type of stent will be ideal in this situation: SEPS (higher complication rate), fully covered SEMS, or biodegradable stent. Lastly, undernourished individuals on chemo-radiation may become more anorectic and not eat despite a stent.

Based on limited studies and some of the issues mentioned above, currently one cannot routinely recommend placing esophageal stents during neoadjuvant therapy as bridge to surgery.

Refractory Benign Esophageal Strictures

Traditionally, endoscopic dilatation with a bougie or a balloon is the method of choice for treating benign esophageal strictures. Around 40% of benign strictures recur[14] and require periodic dilatations. Complex strictures defined as >2cm in length with tortuous configuration and tight enough not to allow a standard endoscope to pass, are difficult to dilate, carry a higher procedural complication rate and tend to recur within weeks.[15,16] Corrosive injuries, radiation, surgery, and esophageal ablative treatments like photodynamic therapy and mucosal resections can lead to the formation of complex strictures. These strictures are hence characterized as Refractory Benign Esophageal Strictures (RBES). The term RBES

<table>
<thead>
<tr>
<th>Length</th>
<th>Internal diameter</th>
<th>Delivery system diameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>90mm, 120mm, 150mm</td>
<td>16mm</td>
<td>12mm (36F)</td>
</tr>
<tr>
<td>90mm, 120mm, 150mm</td>
<td>18mm</td>
<td>13mm (39F)</td>
</tr>
<tr>
<td>90mm, 120mm, 150mm</td>
<td>21mm</td>
<td>14mm (42F)</td>
</tr>
</tbody>
</table>

*Polyflex stent is the only stent cleared by FDA for treating benign esophageal strictures.
was loosely used in the past but currently the most accepted definition is an anatomic fibrotic esophageal restriction, absence of inflammation or motility disorder, with inability to achieve a diameter of ≥14mm in five sessions of dilatations at 2-week intervals or inability to maintain a diameter of ≥14mm for 4 weeks once ≥14mm diameter is achieved. [17] Until now, high-risk dilatations, surgery with associated morbidities and mortalities or life-long G-tube feedings were some of the only alternatives left for these unfortunate patients. Recently newer endoscopic approaches like using expandable esophageal stents have been tried but there are no major prospective randomized studies comparing their efficacies and most of the data available are based on small series.

The Concept of using Stents

If a few seconds of stretching with a bougie or a balloon can give relief for several weeks, then stretching continuously for several weeks conceptually may give longer lasting benefits. This may give enough time for the tissue to remodel around the dilator. Expandable esophageal stents are ideal in stretching the stricture continuously for weeks while maintaining luminal patency. However, unlike malignant strictures, the stent should be a removable stent if used for benign indication. Self-expanding esophageal stents that have been tried for RBES are metal stent (partly covered and fully covered), plastic stents and biodegradable stents.

Partly Covered Self-expanding Esophageal Metal Stent

SEMS are usually coated with plastic to prevent tumor in-growth and have short uncovered segments at the proximal and distal ends for tissue in-growth to allow for better anchoring. Although this feature reduces the risk of stent migration it makes removal of the stent difficult and high-risk. This may not be an issue for those where SEMS are placed permanently for palliation of advanced malignant dysphagia. For RBES, if stents are not removed, they may erode into the mediastinum including the aorta. Other significant complications with long-term stenting include ulceration, bleeding, fistula and recurrent dysphagia due to migration, granulation tissue and new stricture formation. Hence partly covered SEMS are not FDA cleared for use in benign strictures. Nevertheless, there are several small retrospective series in the literature where these stents were used for RBES with very poor results. In review of 29 patients where SEMS were placed for RBES, the overall complication rates noted were up to 80% which included new stricture formation (40%), migration (31%), and trachea-esophageal fistula (6%).[18] In another smaller series, 4 of 8 patients, developed major complications and one patient died from bleeding secondary to the stent eroding into the aorta.[19] Similar discouraging results have been noted in several other small series.[20-22] Besides not being approved for benign indications, and due to unacceptable complication rates, partially covered SEMS are not recommended for RBES.

Self-expanding Esophageal Plastic Stents

A fully covered self-expanding plastic esophageal stent (POLYFLEX®, Boston Scientific Corporation, MA, USA) is now available and FDA cleared it for removal indications. This stent is made of polyester mesh with an outer covering of a silicone membrane. Since plastic material induces less granulation tissue reaction and the full covering prevents tissue in-growth, this stent is removable and hence can be used for benign esophageal strictures.
Initial success rates reported on its efficacy in treating benign esophageal strictures were as high as 80% with minimal complications.[23–25] Subsequent studies form other centers could not reproduce these results.[26,27] On the contrary, these subsequent studies showed poor cure rates with significant associated complication rates which included migration, hemorrhage, chest pain, ulceration and esophageal perforation. These variable results could be due to these studies enrolling patients with different definitions of RBES, variable periods for which the stents were kept in place and the retrospective nature of the design.

In a recent prospective study,[28] 40 patients fulfilling the definition of RBES[16] were enrolled. A SEPS (Polyflex) was deployed across the stricture and then removed after 4–6 weeks of continuous dilatation. At a median of 53 weeks follow up, 30% of patients were dysphagia-free. Another 30% of patients with recurrence of dysphagia after stent removal opted for reinsertion of a new Polyflex stent for a longer duration rather than going back to their baseline alternatives of repeated frequent dilations, G-tube feeding or surgery. Hence, this approach was able to change the outcomes from baseline alternatives in over 50% of patients. Unfortunately complications in the form of migration, chest pain, bleeding and perforation were observed in over 30% of patients and there was a mortality in one patient who refused stent removal and died of severe bleeding probably related to an aorto-esophageal fistula. A recent study compared Polyflex stent to repeated dilations. Both approaches were equally effective in relieving dysphagia but Polyflex stent group required lower number of dilations.[29]

With the available data, it is not clear how the etiology of the RBES influences the outcomes and what is the optimum duration for which the SEPS should be kept in place. This approach is associated with relatively high complication rates and hence should be considered in select patients and that to preferably in a research protocol.

**Fully Covered Self-expanding Esophageal Metal Stent**

Some of the fully covered SEMS available in the US are the Alimaxx-E, Merit Co, Colorado, Wallflex, Boston Scientific, MA, and Nitis-S, TaeWoong. As of writing this review, these stents are not FDA cleared for use as removable stents. However, the plastic coating along the full length of the stent prevents tissue ingrowth and hence these stents are potentially removable. The wire mesh design can get constrained to a thinner diameter compared to a plastic mesh. Unlike the Polyflex stent, they come pre-loaded and the delivery system is thinner in diameter.

As a proof of principle, studies on pigs, showed that Alimaxx-E stents can be removed.[30] Alimaxx-E stent was successfully placed and removed in a small series of 9 patients and in another small series of 7 patients, the success rate in treating the strictures with this stent was reported to be around 29%.[31,32] Stricture recurrence rate of 40% has been reported with Nitis-S stent. New stricture formation, migration and broncho-esophageal fistula were some of the complications observed.[33,34] Data of fully covered Wallflex stent for RBES is awaited as of writing this review.

**Biodegradable esophageal stents**

Biodegradable stents are made of polylactide/polydioxanon. These stents are uncovered and hence tissue ingrowth can anchor the stent. Once anchored, the stent cannot be removed but this is not a major issue as the material used to make these stents is metabolized and hence these stents are biodegradable. There is limited data on its loss of radial force over time. Initial results on using these stents for RBES has been encouraging.[35] This stent is not approved for use in the US.

**Non-Malignant Esophageal Perforations, Leaks, Fistulae**

Esophageal perforation can be spontaneous or iatrogenic. Leaks are generally seen with anastomotic surgery following esophageal resection and these leaks can evolve into fistulae. Early recognition and intervention before mediastinitis sets is the key to improving outcomes. Surgery is still considered to be the primary option in majority of these patients. However, surgery can be associated with significant morbidity and mortality especially in the elderly with multiple medical problems. Covered SEMS or SEPS can offer a minimally invasive alternative to surgery and these stents can be placed at times even as an out-patient procedure. Feedings can be started immediately if radiology study shows no leak. Frequently iatrogenic perforations happen during dilatation of strictures and stents can also be useful in managing the stricture besides the leak.

In a series of 11 patients with traumatic esophageal perforation, stents completely sealed the perforation in 9 patients. In those where the diagnosis was delayed by over 24 hours, chest drains were placed.[36] In another series, perforation closure was successful in 12 of 13 patients within 3 weeks with no complications.[37] In 17 patients with iatrogenic perforations, SEPS sealed the leaks in 16 patients.[38] Similar to iatrogenic and traumatic perforations, stents have also been used for spontaneous perforations (Boerhaave’s syndrome) with encouraging results.[39,40] However the case series are much smaller and no firm conclusions can be made. In a recent prospective study, 33 patients with esophageal perforations (iatrogenic 19, Boerhaave’s syndrome 10, others 4) were treated with various types of covered expandable esophageal stents.[41] Complete and immediate sealing of the perforation was observed in 32 (97%) patients. Four patients required esophageal resections for failed therapy. Complication included stent migration (33%) and technical difficulties in stent extraction in those where the stent was kept in place for over 6 weeks or were partially uncovered. Interestingly the 90-day mortality rate was 15%. Since this was a non-
randomized study, comparable mortality rates with surgery in this group is not known.

Expandable stents have also been tried for anastomotic leaks and fistulae. Most of these studies have shown encouraging results (success rates over 80%) but no firm conclusions can be made as these are small case series.[42-44]

Variceal Hemorrhage

In an interesting approach to control refractory variceal bleeding, Wright et al treated 9 patients with SEMS. Six of the 9 patients survived the acute bleeding episode and had the stent removed endoscopically at a median of 9 days. Stent failed to control the bleeding in 3 patients, 2 of whom had gastric varices. Although this is an interesting approach, it may not be feasible to apply as stenting and removing stents requires expertise and stent are significantly more expensive than Sengstaken-Blakemore tubes especially when considering third-world countries. Moreover, stent can only tamponade esophageal but not gastric varices.[45]

Conclusion

Stents were primarily introduced for palliating dysphagia due to advanced esophageal malignancies. With the introduction of expandable esophageal stents that can be removed or have the potential for removability, there has been a great interest in using stent for benign indications. The attraction lies in the fact that stents can be placed and removed endoscopically using minimally invasive techniques, frequently performed as an out-patient procedure, compared to alternatives like surgery that carry a high morbidity and mortality rate. The benefits are immediate but the long-term durability of this benefit is not known. Based on the current literature comprising mostly of non-randomized, retrospective small case series no firm recommendations can be made. Early indications are encouraging for RBES and esophageal perforations, leaks and fistulae. No data in available on the influence of the etiology of early recurrence of benign esophageal strictures.

References

Role of Self Expanding Esophageal Stents


